ClinicalTrials.Veeva

Menu

Etiology and Hemodynamic Instability in Brain Death

A

Antalya Training and Research Hospital

Status

Completed

Conditions

Brain Death

Treatments

Other: VIS, TIES

Study type

Observational

Funder types

Other

Identifiers

NCT06569992
2024-CeylanM.Braindeath

Details and patient eligibility

About

Brain death is a complex and irreversible condition marked by the cessation of all brain activity. This retrospective study analyzes ICU patients who progressed from initial brain injury to brain death. The research focuses on demographic profiles, pharmacological interventions, laboratory data, and imaging findings to understand these cases clinical trajectories and therapeutic responses. Central to this study is evaluating cardiovascular support using the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure (TIE) Score. This study explores the relationship between the etiology of brain death and the pharmacologic cardiovascular support administered, as quantified by VIS and TIES scores. This study seeks to enhance the management strategies and improve outcomes for patients diagnosed with brain death

Full description

This study undertakes a comprehensive retrospective analysis of patients admitted to the intensive care unit (ICU) with an initial diagnosis of brain injury who subsequently progressed to brain death. The investigation will meticulously assess these patients, demographic profiles, pharmacological interventions, laboratory parameters, and radiological imaging findings. The overarching aim is to delineate the clinical trajectory and therapeutic responses of patients diagnosed with brain death, critically evaluating the complexities encountered during their management, and providing evidence-based insights to inform future treatment protocols.

Central to this study is the quantitative assessment of hemodynamic stability using the Vasoactive-Inotropic Score (VIS) and the Total Inotrope Exposure (TIE) Score. The VIS will quantify the need for vasopressor and inotropic support, reflecting the severity of cardiovascular instability. At the same time, the TIE Score will measure the cumulative exposure to inotropic agents, providing a comprehensive evaluation of the overall cardiovascular burden. The primary aim of this study is to explore the relationship between the etiology of brain death and the pharmacologic cardiovascular support administered, as quantified by VIS and TIES scores. Additionally, the study will assess how these pharmacologic interventions differ in patients who have undergone decompressive surgery compared to those who have not.

This thesis aspires to make a significant contribution to the optimization of management strategies for patients diagnosed with brain death, aiming to enhance clinical decision-making and improve patient outcomes in this critically ill cohort.

Enrollment

216 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (≥18 years) admitted to the intensive care unit (ICU) at Antalya Training and Research Hospital between 2019 and 2023.
  • Patients with a confirmed diagnosis of brain death based on a positive apnea test and/or neuroimaging findings.
  • Patients with comprehensive and complete clinical data available in the hospital's medical records.

Exclusion criteria

  • Patients under the age of 18.
  • Patients with incomplete clinical data in the medical records.
  • Patients with moderate to severe heart failure.
  • Patients with major organ injuries in addition to traumatic intracranial hemorrhage.
  • Pregnant patients.
  • Patients with significant comorbidities that could impact hemodynamic stability.
  • Patients experiencing hemodynamic instability due to septic shock.
  • Patients who were initially treated for brain injury at external facilities and later transferred to our hospital.

Trial design

216 participants in 3 patient groups

Group 1
Description:
Spontaneous subarachnoid hemorrhage and spontaneous intracerebral hemorrhage
Treatment:
Other: VIS, TIES
Group 2
Description:
Traumatic intracranial hemorrhage
Treatment:
Other: VIS, TIES
Group 3
Description:
Ischemic cerebrovascular events and hypoxic-ischemic brain injury (including cases of cardiac arrest, drowning, carbon monoxide poisoning, etc.)
Treatment:
Other: VIS, TIES

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems